Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Down syndrome is frequently associated with cognitive impairment and dementia.
• Acetylcholinesterase inhibitors like donepezil are used to treat cognitive decline.

Observation:

• Two cases of patients with Down syndrome and severe cognitive impairment receiving donepezil treatment are presented.
• Case 1: A 38-year-old woman experienced dramatic QOL improvements and regained lost communication skills with a 3 mg/day dose after initial adverse effects at 5 mg/day.
• Case 2: A 22-year-old man with severe mental retardation showed significant QOL improvement and partial recovery of verbal communication with a 3 mg/day dose, despite transient side effects.

Findings:

• Donepezil treatment resulted in dramatic improvements in quality of life (QOL) for both patients with Down syndrome.
• Patients with Down syndrome may exhibit increased sensitivity to donepezil, requiring careful dose titration to manage adverse effects.
• Minimal effective doses (3 mg/day) were sufficient for significant clinical benefit in these cases.

Implications:

• Donepezil may be a viable therapeutic option for managing severe cognitive impairment in select patients with Down syndrome.
• Individualized dosing and monitoring are crucial to optimize benefits and mitigate risks associated with donepezil therapy in this population.
• Further research is warranted to explore the efficacy and safety of donepezil in a larger cohort of individuals with Down syndrome.